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Abstract
Novel methods to analyze the tumor microenvironment (TME) are urgently needed to stratify 
melanoma patients for adjuvant immunotherapy. Tumor infiltrating lymphocyte (TIL) analysis, by 
conventional pathologic methods, is predictive but is insufficiently precise for clinical application. 
Quantitative multiplex immunofluorescence (qmIF), allows for evaluation of the TME using 
multiparameter phenotyping, tissue segmentation, and quantitative spatial analysis (qSA). Given 
that CD3+CD8+ cytotoxic lymphocytes (CTLs) promote antitumor immunity, whereas CD68+ 
macrophages impair immunity, we hypothesized that quantification and spatial analysis of 
macrophages and CTLs would correlate with clinical outcome. We applied qmIF to 104 primary 
stage II-III melanoma tumors and found that CTLs were closer in proximity to activated 
(CD68+HLA-DR+) macrophages than non-activated (CD68+HLA-DR−) macrophages (p<0.0001). 
CTLs were further in proximity from proliferating SOX10+ melanoma cells than non-proliferating 
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ones (p<0.0001). In 64 patients with known cause of death, we found that high CTL and low 
macrophage density in the stroma (p=0.0038 and p=0.0006, respectively) correlated with disease-
specific survival (DSS), but the correlation was less significant for CTL and macrophage density 
in the tumor (p=0.0147 and p=0.0426, respectively). DSS correlation was strongest for stromal 
HLA-DR+ CTLs (p=0.0005). CTL distance to HLA-DR− macrophages associated with poor DSS 
(p=0.0016), whereas distance to Ki67− tumor cells associated inversely with DSS (p=0.0006). A 
low CTL/macrophage ratio in the stroma conferred a hazard ratio (HR) of 3.719 for death from 
melanoma and correlated with shortened overall survival (OS) in the complete 104 patient cohort 
by Cox analysis (p=0.009) and merits further development as a biomarker for clinical application.
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Introduction
Cutaneous melanoma is an aggressive disease, even when localized, with 40% of patients 
with stage II-III melanoma developing recurrent disease (1). Current histopathologic 
methods, including conventional immunohistochemistry (IHC) evaluation of formalin-fixed 
paraffin-embedded (FFPE) tissues, have been unable to identify precise biomarkers capable 
of identifying patients at greatest risk for recurrence (2). Advancements in clinically 
applicable histopathologic methods for evaluating the tumor microenvironment (TME) are 
essential for patient care and, in particular, selecting patients to receive immunotherapies. In 
pre-clinical research settings, flow cytometry (FC) offers detailed evaluation of infiltrating 
immune cells and supplements conventional IHC. However, clinical application of FC is 
limited because FC can only be performed on fresh tissue. Obtaining fresh tissue is only 
feasible when a large volume of excess tumor is available, a rare occurrence for primary 
melanomas, and harvesting fresh tissue requires close coordination between multiple 
clinicians in an already overburdened health care setting. In contrast, FFPE samples are 
routinely banked on every patient who has tumor resection and/or biopsy and is a much 
more practical source of material for immune phenotyping.
In early stage melanoma, traditional tumor, node, and metastasis (TNM) staging does not 
precisely assess the risk of recurrence of an individual patient. The American Joint 
Committee on Cancer (AJCC) defines stage II melanoma based on tumor depth >1.01mm 
with ulceration and >2.01mm with or without ulceration, and stage III disease is defined by 
locoregional metastasis (1, 3). Stage III disease is further sub-classified based on volume of 
lymph node metastasis (1, 3). Unfortunately, complete staging is often not performed 
because patients are reluctant to undergo lymph node dissection, particularly in light of 
studies demonstrating insignificant impact on clinical outcomes (3, 4). Even for patients who 
do undergo full clinical staging, a high degree of heterogeneity among patients within the 
same stage group remains, evidenced by the 50% survival rate at 5 years for stage IIC 
disease (1). Thus, significant limitations to traditional stage classification in melanoma exist, 
impeding identification of high-risk patients who might be expected to obtain the greatest 
benefit from either enhanced radiographic surveillance or adjuvant immunotherapy (IO).
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IO, which has changed the clinical landscape of metastatic melanoma, is most effective in 
lower disease burden, when tumor-mediated immunosuppression is minimal (5). Thus, IO 
has the potential to be effective in the adjuvant setting. However, although these agents have 
demonstrated efficacy in melanoma, they also introduce the potential for immune adverse 
effects (IAE), including colitis, pneumonitis, and myocarditis (6, 7). In the metastatic setting 
there is a higher tolerance for IAEs. However, the lack of precise predictive tools has 
contributed to stalling the application of IO to the adjuvant setting due to both the safety 
concerns and expense of conducting these trials in large populations that include many low-
risk patients. Thus, prognostic biomarkers are urgently needed to identify which patients are 
at greatest risk for recurrence and for stratification of clinical trials (8).
Tumor-infiltrating lymphocytes (TILs), a heterogeneous group of lymphocytes within the 
TME, are a positive prognosticator in melanoma (9-16). TIL assessment, however, is subject 
to significant inter-observer variability, thus, limiting clinical utility (11, 12). Detailed 
analysis of TILs shows that CD8+ cytotoxic T lymphocytes (CTLs) correlate best with 
survival, but generalizable and reproducible methods to analyze TIL composition have not 
yet been developed (17). Other cells of importance in the TME are macrophages. Although 
the role of macrophages has been controversial, discrepancies in reported data is attributable 
to diverse subgroups of macrophages that either support an effective antitumor response (M1 
type) or promote tumor growth (M2 type)(18-21). M2 macrophages are capable of 
producing enzymes, including indoleamine-pyrrole 2,3-dioxygenase (IDO) and arginase, 
which inhibit CTL activity through tryptophan and L-arginine depletion (22). M2 
macrophages have also been found to express PD-L1,the known inhibitory ligand of the 
PD-1 receptor found on T-lymphocytes (20). In addition to modulating CTL function, 
macrophages are implicated in tumor growth, demonstrating capacity to promote 
neovascularization through production of angiogenic peptides, including VEGF (23). Given 
that these immunosuppressive mechanisms require either direct contact or close proximity to 
CTLs, strong biologic rationale exists for pathologic approaches capable of evaluating the 
spatial relationships between these immune subsets. Although proximity analysis is a limited 
surrogate for potential cellular interactions, prior clinicopathologic data in melanoma 
supports the utility of analyzing spatial localization of immune cells within tumors (24). 
Thus, the immune score takes into account the position of lymphocyte infiltration within the 
TME. Macrophage infiltration, specifically when present at the invasive front but not within 
the tumor as a whole, has been shown to correlate with poor survival in stage I/II disease 
(25). Although CTLs are known to play a protective role and macrophages a deleterious one, 
these findings have not been applied to clinical practice (26, 27).
In order to address the need for detailed phenotyping of immune infiltrates in FFPE samples, 
we apply quantitative multiplex immunofluorescence (qmIF) to analyze the TME in primary 
melanoma tumors (28). QmIF employs a serial IHC approach that includes the application 
of fluorophores of distinct wavelengths, allowing for staining and visualization of multiple 
antigens within the same tissue specimen. Subsequently, multispectral, high-resolution 
images are obtained, which are then analyzed using machine learning algorithms. This 
approach allows for more sophisticated computational analysis, including automated 
phenotyping for objective density and spatial assessment of immune cell phenotypes within 
the TME (28-35). QmIF requires iterative training to develop tissue and cell classification 
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algorithms (Supplementary Fig. S2-5) and can ultimately augment analysis capacities 
beyond traditional IHC evaluation (31-33, 35).
In addition to enhanced automated quantitation of cell phenotypes over manual review by a 
pathologist, qmIF is capable of analyzing cells based on tissue segmentation to determine 
whether cells are located in tumor or stromal compartments. Digital pathology using qmIF 
offers the ability to perform quantitative spatial analysis (qSA) to evaluate the proximity of 
individual immune cell subsets to each other, as well as to tumor cells (28). Precise tissue 
segmentation and localization of immune cells is not evaluable with traditional IHC because 
the manual nature of analysis is inherently subjective and introduces observer bias. Digital 
pathology approaches, employing machine-based learning algorithms to evaluate large tissue 
areas and complex cell phenotypes, have been validated across multiple solid tumor types 
(28-38). Several studies employ qSA to study tissue segmentation and distance relationships 
of multiple cell phenotypes (32, 33, 36-39). The importance of tissue segmentation to define 
precise location of lymphocytes within the TME is established by the Immunoscore method, 
wherein the leading edge of the tumor is differentiated from the center of the tumor (2). 
However, location of the leading tumor edge generally requires expert pathology guidance. 
Thus, Immunoscore has not been applied to primary melanoma, in part, because it is 
complicated to reproducibly define the leading edge in these small and heterogeneous 
neoplasms (8, 32-35). Prior IHC work, including Immunoscore, does not provide qSA of the 
location of immune cells relative to other cells within the tumor.
In prior work, to more comprehensively characterize the TME, as well as identify a 53 
immune gene mRNA panel, our group applied a NanoString assay, comprised principally of 
genes associated with a Th1 immune response, which correlates with disease-specific 
survival (DSS) in two independent patient populations (13). NanoString assays are both 
quantitative and non-subjective but are more costly than IHC and require homogenization of 
tissue, precluding evaluation of spatial localization of immune cells. Although the 
NanoString data did not suggest a prominent role for macrophage lineage cells in tumor 
progression, this might have been due to the lack of information regarding spatial 
localization of the macrophages. We hypothesized that further spatial characterization of the 
macrophages, together with additional phenotypic markers, might clarify the role of 
macrophages in tumor progression. For example, macrophages at the leading tumor edge 
mark high-risk patients (40). Markers of activation and antigen presentation, including HLA-
DR, aid in the separation of macrophage phenotypes, such that HLA-DR− macrophages are 
more likely to be inflammatory and HLA-DR+ macrophages are more likely to favor 
antitumor immunity (41-43).
Thus, to further expand our capacity to assess the TME, we use qmIF to evaluate stage II-III 
primary melanoma. We included CTLs and macrophages as proposed biomarkers, while 
adding HLA-DR and Ki67 for further evaluation due to previous studies showing the 
addition of these markers to be important features of immune cell activation (8, 30, 40, 44). 
Ina cohort of 104 patients (Table 1), we performed tissue segmentation, cellular 
phenotyping, automated density, and qSA of immune cell subsets. We find that low CTL/
macrophage ratio in the stroma correlated with shortened DSS and overall survival (OS) in 
stage II-III melanoma.
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The study was approved by Columbia University Medical Center's (CUMC) Institutional 
Review Board. A patient database of stage II-III melanoma patients at CUMC was created 
retrospectively by searching surgical pathology records from 2000-2012 for “melanoma”. 
Dermatopathology reports were first screened retrospectively for tumor size, finding tumors 
1.01– 2.00 mm with ulceration and 2.01 – 10mm. After reviewing 1139 patient records, we 
identified 765 stage II-III patients. Of these 765 patients, 219 had available survival data, 
defined as known date of death and/or 24 months documented clinical follow-up. 
Hematoxylin and eosin (H&E) slides were reviewed with a dermatopathologist, and 183 
patients had confirmed tumors, whereas 36 had no melanoma in the residual specimen. Wide 
local excision and post biopsy specimens were excluded due to concerns for immune 
infiltrate post biopsy, thus, leaving 142 patients. During the staining process 17 were lost due 
to tissue destruction, 19 had staining artifact, 4 were too small, and 2 were unable to be 
analyzed using the image analysis software, leaving a total of 104 analyzable samples 
(Supplementary Fig. S1 and Supplementary Table S1). 104 patients were analyzed (Table 1), 
64 with known recurrence status at the time of last follow-up or death (Supplementary Table 
S2), and 40 patients with unknown cause of death. This cohort consists of more stage II 
(n=91) than stage III (n=13) and more males (n=75) than females (n=29). Median depth was 
2.5 mm, and 65% of tumors were ulcerated. 59 and 33 patients had non-brisk TILs and brisk 
TILs, respectively, as determined by dermatopathologist (BH), whereas 2 had absent TILs 
and 10 were not assessed due to absence of the tumor base (16).
Staining
Full section 5 μm slides of tissue specimens were stained using Opal™ multiplex 6-plex kits, 
according to the manufacturer's protocol (PerkinElmer), for DAPI, CD3 (clone LN10; Leica 
(Buffalo Grove, IL); 1:200 dilution), CD8 (clone 4B11; Leica; Ready to use (RTU)), CD68 
(clone KP1; Biogenex (Fremont, CA), RTU); SOX10 (clone BC34; Biocare (Pacheco, CA); 
1:300), HLA-DR (clone LN-3; Abcam (Cambridge, MA); 1:200 dilution), and Ki67 (clone 
MIB1; Abcam; RTU). Opal multiplexing is a serial immunohistochemistry method that 
relies on tyramide signal amplification (TSA)(30, 45), which creates an amplification of 
signal that then covalently binds to the epitope in a specific manner (27, 46). Primary and 
secondary antibody complexes are subsequently removed for serial immunofluorescence, 
while the covalent fluorescent signal remains. Single controls and an unstained slide were 
stained with each group of slides.
Multispectral Imaging
H&E slides were viewed by a dermatopathologist to determine representative areas for 
multispectral image capture at 20× magnification using Mantra™ (PerkinElmer Images were 
analyzed using inform™ software (PerkinElmer) (Fig. 1A-G, Supplementary Fig. S2-5). 
Five representative areas were chosen by the dermatopathologist: (i) three areas with tumor 
and up to 50% stroma and (ii) two areas with tumor only (at least 90% tumor). These images 
were factored equally into the analysis for each patient. Mantra™ captures spectral 
information from a multiplexed panel of targets using a multispectral camera. For samples of 
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small size, a minimum of two areas meeting the above criteria were required for inclusion. 
For spectral unmixing, examples of each fluorophore are taken from single stained slides for 
each antibody, as well as a representative autofluorescence spectrum from an unstained 
sample. Images from each of these single-stained and unstained slides were used to create a 
multispectral library in inform™. Intensity of each fluorescent target was extracted from the 
multispectral data using linear unmixing (47).
Image Analysis
Images were analyzed using inform™ software (PerkinElmer) (Fig. 1A-G). Tissue 
segmentation was performed by highlighting examples of SOX10+ tumor and SOX10− 
stroma or non-tumor tissue, allowing the algorithm to ‘learn’ each tissue type and segment 
image based on gross morphology (Fig. 1D and Supplementary Fig. S2). Supplementary 
Fig. S2 provides example of tissue segmentation using SOX10 for five images from a single 
patient. Cellular and subcellular compartments were defined by a counterstain (DAPI) to 
define the nucleus of each cell (Fig. 1B), with each associated membrane detected via 
presence of a specific stain (CD3, CD8, or CD68) (Fig. 1C). Cell segmentation was adjusted 
based on minimum DAPI signal to accurately locate all cells, splitting of cells in order to 
avoid hypersegmentation and hyposegmentation, and growing and shrinking the nuclei to fit 
both tumor and immune cells (Fig. 1A-C and Supplementary Fig. S3). Supplementary Fig. 
S3 shows each of the five images from a single patient with associated DAPI and cell 
segmentation of the whole 20× image, as well as a zoomed image of the top right corner 
showing both DAPI and cell segmentation enlarged. Cells were then phenotyped by using 
the phenotyping step of inform™. 10 – 15 cells for each base variable were selected to train 
the phenotyping algorithm: tumor (SOX10+, red dots), T cells (CD3+, cyan dots), 
macrophages (CD68+, green dots), and other (negative for SOX10, CD3, and CD68, blue 
dots) (Fig. 1E and Supplementary Fig. S4). Supplementary Fig. S4 shows representative 
phenotyping of five images for a single patient. The last step in inForm was scoring. The 
images were scored for intensity based on each individual secondary marker for further 
phenotyping of HLA-DR, CD8, and Ki67 (Fig. 1F and Supplementary Fig. S5). 
Supplementary Fig. S5 shows scoring in the tumor and stroma for CD8 on five images from 
a single patient. Finally, data obtained from all representative images was compiled to yield 
values for each patient. Image data was exported from inform™ version 2.2.1 (PerkinElmer, 
Hopkinton, MA). The inForm data from all images for each patient were processed in 
separate software designed in R Studio (version 0.99.896, Boston, MA) (https://github.com/
thmshrt/transform_essential). In this software, images were combined and analyzed to 
concatenate variables (i.e. CD3+CD8+HLA-DR+) and determine density and distance of 
distinct phenotypes. High and low CTL and macrophage density was defined as above and 
low a cutoff defined by CART analysis, as well as determined using ROC curves and AUC 
cutoff.
Statistical Analysis
Analysis was completed with GraphPad Prism Version 7.02 (GraphPad software, La Jolla, 
CA), and statistical significance was defined as p≤0.05. The need for multiple comparison 
correction was bypassed by considering unique nearest neighbors in the analysis, which was 
analyzed using R Studio Version 0.99.896 (CRAN, Boston, MA) and Spotfire software 
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(TIBCO, Palo Alto, CA). Unique nearest neighbor analysis was applied to define spatial 
relationships between cellular phenotypes. Median distance was calculated across all images 
for each patient (13).
The effect of the density and distance of immune cell subsets on survival was further 
analyzed using Classification and Regression Tree (CART) analysis. Kaplan–Meier curves 
were obtained for DSS and OS in R Version 3.3.1 (CRAN, Boston, MA). P values were 
calculated using the log-rank (Mantel–Cox) test. Receiver Operating Characteristic (ROC) 
curves, standard univariate and multivariate Cox proportional hazards analysis, and Pearson 
correlation matrix testing were performed using R Studio.
Results
CTLs are closer to non-dividing tumor cells and to activated macrophages
We first sought to characterize the TME in primary melanoma using qmIF. Based on 
published data suggesting that CTLs limit cancer progression, whereas macrophages 
promote it, we selected CTLs and macrophages as candidate biomarkers (40). We analyzed 
104 primary tumors for total number of CTLs and macrophages in both tumor and stroma 
(Fig. 1H). In order to characterize the level of activation of these cell types, we also included 
HLA-DR, a marker of cellular activation previously shown to predict response to anti-PD1 
therapy, and Ki67, a marker of cell division (11, 40). CTLs and macrophages were evaluated 
based on expression of HLA-DR (Fig. 1H). All immune cells analyzed were significantly 
more prevalent in the stroma than in the tumor (Fig. 1H).
We next applied qSA, using nearest neighbor analysis to evaluate relationships between 
expression of Ki67 and HLA-DR on macrophages and tumor cells and spatial localization of 
these cells to CTLs. We found that CTLs were spatially closer to tumor cells when they were 
not proliferating (Ki67−) (p<0.0001; Fig. 1I, left). When evaluating each patient 
individually, we showed CTLs were closer to non-proliferating tumor cells in nearly all 
samples having both Ki67+ and Ki67−tumor cells (n=86; Fig. 1I, right). This result is 
consistent with literature showing that melanomas with higher rates of proliferation have 
lower frequencies of infiltrating CTLs (18).
We found that HLA-DR is expressed on CD68+ macrophages, CTLs, and, as previously 
reported, melanoma cells (9). We evaluated the distance of CTLs to SOX10+ tumor and 
CD68+ macrophages using nearest neighbor analysis. We found that CTLs were closer to 
CD68+ macrophages when they were HLA-DR+ (p<0.0001; Fig. 1J, left). The median CTL 
distance to macrophages is shown for individual patients matched for both HLA-DR+ and 
HLA-DR− cells (n=97; Fig. 1J, right). HLA-DR expression on tumor cells did not 
significantly impact distance to CTLs (p=0.0846; Supplementary Fig. S6A).
CTL infiltration correlates inversely with risk of death from melanoma
Among the 104 patients included, we performed a subset analysis on 64 patients for whom 
cause of death was known (Supplementary Table S2) to determine whether density of CTLs 
in tumor or stroma correlate with DSS. Marked differences in the density of CTLs was 
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observed between patients, as depicted in Fig. 2A and B with tumor specimens 
demonstrating high and low CTL infiltration, respectively.
We next evaluated density of CTLs in the stroma and tumor using CART analysis to 
determine whether density could stratify patients in terms of DSS. Specifically, using CART 
cutoffs, we created KM curves to assess the effect of CTL density on DSS in both tumor and 
stroma. We found that a high density of CTLs in the stroma (p=0.0038) and tumor 
(p=0.0147) correlated with DSS (Fig. 2C and D), consistent with prior reports that CTLs 
conferred favorable prognosis (10-12, 17, 43). We next evaluated whether subsets of CTLs 
might predict prognosis more accurately. The density of CTLs expressing HLA-DR 
(activated T cells) correlated significantly with DSS in the stroma (p=0.0005; Fig. 2E) but 
was less significantly correlated in tumor (p=0.0167; Fig. 2F). Ki67-expressing CTLs, 
however, did not correlate with DSS in the stroma (p=0.1737; Supplementary Fig. S6B) or 
tumor (p=0.2161;Supplementary Fig. S6C). Thus, assessment of an activation marker 
appeared to enhance correlation with DSS, whereas including a proliferation marker reduced 
the correlation between CTL density and DSS.
We further analyzed CTLs by evaluating their distance to proliferating (SOX10+Ki67+) and 
non-proliferating (SOX10+Ki67−) tumor cells. As stated above (Fig. 1I), CTLs were 
preferentially located closer to SOX10+Ki67− cells. We found that close distance of CTLs to 
non-proliferating tumor cells (Ki67−) stratified DSS (p=0.0006; Fig. 2G). However, the 
distance of CTLs to proliferating tumor cells (Ki67+) did not significantly correlate with 
DSS (p=0.0618; Fig. 2H). The distance of CTLs to tumor cells, with or without HLA-DR 
expression, also did not effect DSS (p=0.8436 and p=0.0899, respectively; Supplementary 
Fig. S6D and E).
HLA-DR− macrophage density correlates with high-risk of death from melanoma
Because we determined that CTLs, particularly in the stroma, correlated with a favorable 
prognosis, we next evaluated density of CD68+ macrophages in each patient with complete 
clinical follow-up. Fig. 3A shows a representative multiplex image from a melanoma tumor 
with CD68+ macrophage infiltrate, and Fig. 3B shows the same image with only CD68 and 
DAPI staining to demonstrate how these cells were visualized. Using CART cutoffs, we 
created KM curves evaluating the effect of CD68+ macrophage density on DSS in both the 
tumor and stroma. In contrast to CTLs, high density of macrophages in the stroma 
(p=0.0006) and tumor (p=0.0426) associated with poor DSS (Fig. 3C and D). Evaluation of 
macrophages with and without HLA-DR, we found that high density of HLA-DR− 
macrophages in stroma (p=0.0013, Fig. 3E) and tumor (p=0.0163, Supplementary Fig. S6F) 
indicated poor DSS. However, density of HLA-DR+ macrophages in the stroma (p=0.0637) 
and tumor (p=0.1027) had no significant impact on survival (Fig. 3F and Supplementary Fig. 
S6G). Thus, CD68+ macrophages in the stroma, but not in the tumor, correlated with DSS, 
and this correlation was substantially driven by the HLA-DR−macrophage subset.
Given that macrophage density associated with poor survival, we next tested whether 
distance of CTLs to macrophages with or without HLA-DR correlated with survival. We 
found that close distance of CTLs to CD68+ HLA-DR− macrophages segregated with shorter 
DSS (p=0.0016, Fig. 3G). Close distance of CTLs to CD68+ HLA-DR+ macrophages also 
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indicated poor prognosis but was less robust (p =0.0388, Fig. 3H). Thus, HLA-DR– 
macrophages in the strom a conferred a poor prognosis, and the distance between HLA-DR− 
macrophages and CTLs also associated with survival, with a shorter distance indicating poor 
outcome.
Low CTL/macrophage is associated with inferior survial in stage II-III melanoma
Because we determined that CTLs associated with prolonged survival, whereas macrophages 
in the stroma associated with shortened survival, we sought to integrate these cell types into 
one biomarker for clinical application. We first tested whether the distance between the two 
most impactful populations in terms of survival, CTLs and HLA-DR− macrophages, 
segregated with clinical outcome. Fig. 4A shows a representative multiplex image of a 
melanoma tumor containing CD68+HLA-DR− macrophages and a selected region 
containing CD68+ HLA-DR− macrophages, designated by white arrows (Fig. 4A, inset). We 
further analyzed and compared distance of CTLs to HLA-DR− macrophages using a ROC 
curve to find the area under the curve (AUC) for death from melanoma over the time of 
follow-up. We found that the distance of CTLs to HLA-DR− macrophages was significant 
via ROC (AUC = 0.682, p=0.011, cutoff = 165.54 pixels; Fig. 4B, left). Using the AUC 
cutoff (165.54) to create a binary analysis of the 61 patients with distance values, excluding 
3 patients with no CTLs, to evaluate DSS and Cox proportional hazards (Supplementary 
Table S3), we found that close distance of CTLs to HLA-DR− macrophages correlated with 
shorter survival (p=0.0077; Fig. 4B, right).
Consistent with our hypothesis that the density of CTLs and macrophages both have a 
significant impact on survival, we sought to analyze the ratio of these cells in each patient to 
create a more clinically impactful biomarker that would also allow us to include patients for 
whom there are no CTLs detected in the sample. We found that a low CTL/macrophage ratio 
was significant for death from melanoma using ROC (AUC = 0.724, p=0.026, cut off = 
2.557; Fig. 5A). We then used the AUC cutoff to create a binary analysis of all 64 patients 
with DSS to analyze, using a KM curve. We found that a low CTL/macrophage ratio 
predicted poor prognosis (p=0.0033; Fig. 5B). Univariable Cox analysis showed that a low 
CTL/macrophage ratio indicated poor prognosis (p = 0.006, Hazards Ratio (HR) = 3.719, 
95% Confidence Interval (CI) = 1.451 - 9.533; Fig. 5D). In this population of 64 patients, 
among other clinical parameters including stage, gender, age, location and depth, only stage 
was found to be significant (Fig. 5D). Multivariable Cox regression was most significant 
when stage, ulceration, and CTL/macrophage ratio were included (p=0.002; Fig. 5D). 
Further analysis found a that low CTL/macrophage ratio also correlated with poor DSS at 
the two-year and five-year time points. specifically (Supplementary Fig. S7).
To further evaluate the robustness of the CTL/macrophage ratio in predicting prognosis, we 
analyzed all 104 patients for OS (note: cause of death was not known for all the patients). 
Using the AUC cutoff (2.557) to create a binary of all patients to evaluate using a KM curve, 
we found that a low CTL/macrophage ratio predicted poor OS (p=0.0076; Fig. 5C). 
Univariable Cox analysis showed that a low CTL/macrophage ratio indicated poor prognosis 
(p=0.009, HR=1.873, 95% CI = 1.170-2.997),whereas all other variables were not found to 
be significant (Fig. 5D). Contrary to DSS, multivariable analysis in the OS cohort of 104 
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patients showed that ulceration and stage did not enhance the robustness of the model 
(p=0.066; Fig. 5D). We found that the CTL/macrophage ratio in the stroma correlated with 
the presence of TILs, using Pearson Correlation Matrix (Table 2). No significant correlation 
between the densities of CTLs and macrophages was found, suggesting that they play 
independent roles in tumor progression (p=0.225, Table 2, Supplementary Table S4).
Discussion
Technological advances using machine learning allow for precise and reproducible 
quantitation of immune populations within the TME using qmIF (30, 41, 48-50). The Opal 
staining method combined with qmIF imaging and analysis, unlike other multiplex methods, 
allows for evaluation using a single slide rather than layering of stains using multiple slides 
(43). Multiplex staining of a single slide using qmIF provides high-resolution of each 
individual cell, thereby, allowing for tissue segmentation, multiparameter phenotyping of 
cells, and precise qSA, all of which was not previously possible. Although pathology 
expertise is required for the initial training algorithm, automation of subsequent image 
analysis minimizes subjectivity of interpretation. Because qmIF offers the advantage of 
using a single slide for processing and automation for analysis, this method will be more 
clinically applicable, especially for predictive biomarkers, and may also be useful 
diagnostically. QmIF has been successfully performed in multiple tumor types, including 
melanoma, breast cancer, lung cancer, and Hodgkin's lymphoma (41, 48-50). Specifically, 
this method was successfully employed using 6-plex qmIF to evaluate 17 patients with 
melanoma, finding that the ratio of CTLs to PD-L1 or FOXP3 is capable of predicting TIL 
generation following adoptive T-cell therapy (51). For our study, we proposed a biomarker 
developed using this technique that incorporates both density assessment, including precise 
tissue segmentation and multiparameter phenotyping, and qSA in early stage melanoma 
patients (13, 52).
We achieved precise tissue segmentation with automated differentiation of tumor from 
stroma through qmIF analysis of the TME. This analysis built on prior IHC literature, 
demonstrating that macrophages in the peri-tumor stroma were more significant to clinical 
outcome than those within the tumor proper. This builds on prior research showing that 
macrophages at the “leading edge” of the tumor are prognostic, but our automated method 
for tissue segmentation allows for potential rapid clinical application across institutions (13, 
24). Because the qmIF method allows for quantification of cells with multiple concatenated 
markers, as well as automated assessment of morphology, we were able to accurately define 
the CTL/macrophage ratio specifically within the tumor-associated stroma, allowing for a 
precise and quantifiable biomarker. The potential for qmIF to allow for qSA exists, by 
evaluating the minimum distance between different cell phenotypes using nearest neighbor 
analysis. Using qSA, we can analyze distance to and from different immune cells, as well as 
immune cell distance to individual tumor cells.
In terms of prognosis, also consistent with prior IHC literature, we found that high density of 
CTLs, particularly in the stroma, was a favorable indicator (13). Specifically, we found that 
CTLs in the stroma were significantly more prognostic than overall CD8 density with both 
ROC and univariable Cox analysis. The fact that CTL density within each compartment of 
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the tissue was more significant than total density without tissue segmentation may indicate 
that there is a biologic difference between tumor and stroma, as identified by our algorithm, 
such that each is best evaluated independently.
The CTL density in the tumor was also favorable but less significant. This may have been 
due to the increased CTL density in the stroma in comparison to the tumor, impacting 
statistical analysis, but may also indicate that the biology of the stroma is more critical for 
progression. Among CTLs, the activated HLA-DR+ subset was prognostic, whereas 
dividing, Ki67+ CTLs had less effects, suggesting that activation status of CTLs impacts 
clinical outcome. Using qSA, our findings showed that CTLs were spatially closer to non-
dividing tumor cells (Ki67−) and activated macrophages (HLA-DR+), consistent with 
established findings that melanomas with a high proliferation rate are less infiltrated (13). 
CTLs may inhibit melanoma differentiation, or rapidly growing tumor may exclude CTLs. 
Close spatial proximity of CTLs to non-proliferating tumor (Ki67−) segregated with good 
DSS, perhaps because proximity allowed for cytotoxic antitumor activity.
Although spatial proximity is a limited surrogate for interaction between cells, our finding 
that close proximity of CTLs to HLA-DR− macrophages was associated with poor survival 
is consistent with the hypothesis that interactions between CTLs and macrophages promote 
inflammation and impair antitumor immunity. Further functional studies are needed to 
delineate the role spatial proximity plays in facilitating cellular communication within the 
TME. In the evaluation of macrophage density segmentation, our findings showed that high 
density of CD68+ macrophages, particularly in the stroma, strongly conferred an unfavorable 
prognosis in stage II-III melanoma and was driven by HLA-DR− macrophages, as HLA-DR
+
 macrophages did not significantly affect prognosis. No direct correlation between CTL 
density and macrophage density was found, implying two distinct biologic processes. 
Macrophages, thus, may cause local tissue destruction, increasing tumor growth via a 
mechanism not directly related to CTLs or antitumor immunity (53-55).
Our proposed biomarker, the CTL/macrophage ratio, is consistent with our original 
hypothesis that CTLs play a favorable role, whereas macrophages play a deleterious one. 
Distance between CTLs and HLA-DR− macrophages was also prognostic, raising the 
possibility that interactions between these two subsets may inhibit immune surveillance by 
the CTLs. Specifically, the stromal CTL/macrophage ratio demonstrated superior prognostic 
value over independent CTL and macrophage density, with the highest AUC on ROC 
analysis. Consistent with prior literature showing that macrophage density within the leading 
edge, but not the center of the tumor, is prognostic, we found no correlation by Cox between 
macrophage density within the tumor and clinical outcome. Thus, focusing on the stroma 
avoids including additional macrophage data that may dilute the predictive power of the 
biomarker.
One limitation to our study was that IHC analysis was subject to an inherent sampling bias 
due to heterogeneity. In order to address tissue heterogeneity, we sampled five representative 
areas determined by a trained dermatopathologist who was blinded to the clinical data. 
Notably, pathologists have been able to reproducibly evaluate TIL infiltration based on 
representative areas of the tumor suggesting that there is limited variability in assessment 
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between pathologists (12, 55). Although pathology expertise is required for the initial 
training algorithm, automation of subsequent image analysis minimizes subjectivity of 
interpretation. In the future, it may be possible to apply additional machine learning 
algorithms to eliminate the role of the pathologist and, thus, any possible subjectivity in 
image selection. A second limitation of our study was that all 104 patients came from a 
single center. We also were not able to analyze 42 patients due to poor tissue quality, 
suggesting that further technical refinement is needed, particularly in specimens stored for 
longer than 10 years and for very small tumors. Validation in additional populations is 
needed for clinical application.
In this work, we present a quantitative analysis combining assessment of multiparameter 
immune phenotypes, tissue segmentation, and qSA in primary melanoma using qmIF. Using 
this method, we also identifed a biomarker for potential clinical application, demonstrating 
the value of this approach. Our findings were consistent with known biology of primary 
melanoma tumors and provide a more quantitative and accurate biomarker in the population 
studied than standard TIL analysis, which demonstrated only borderline significance. An 
accurate prognostic clinical biomarker in early stage melanoma is needed to select patients 
in the development of therapeutic adjuvant protocols. This is of particular importance given 
that melanoma may recur years after diagnosis, further complicating the development of 
predictive biomarkers in an ever-changing immunotherapy landscape. QmIF as a platform 
has significant, and untapped, potential for defining novel biomarkers. The CTL/macrophage 
ratio in the stroma of primary melanoma tumors merits further development as a biomarker 
for clinical application.
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Figure 1. Characterization of the tumor immune microenvironment with qmIF, including 
evaluation of spatial distribution of CTLs relative to tumor cells and CD68+ macrophages
Processing of slides done in inform™ (Perkin Elmer). Steps for analysis using inForm 
represented using a single image from one patient. A) Multiplex image of a melanoma 
stained using qmIF. DAPI (nuclei, blue), SOX10 (tumor, red), CD3 (T cells, cyan), CD8 
(CTLs, magenta), CD68 (macrophages, green), Ki67 (proliferation marker, yellow), HLA-
DR (activation marker, orange). B) Area from the multiplex image (marked by white inset) 
zoomed in as DAPI only. C) Cell segmentation of zoomed DAPI image. (D-G) are 
representative analysis steps of the image in (A). D) Tissue segmentation. E) Phenotyping 
showing base phenotypes:macrophages (green), T cells (cyan), Tumor (red) and Other 
(blue). F) Scoring with representation of HLA-DR scoring (orange). G) Representative 
visual example of Nearest Neighbor Analysis to evaluate distance between CD3+CD8+ 
(pink) and SOX10+Ki67+ (yellow). H) Density of CTLs and CD68+macrophages (n=104). 
CD3+CD8+ (far left, p<0.0001); CD3+CD8+HLA-DR+ (middle left, p<0.0001); CD68+ 
(middle right, p<0.0001); CD68+HLA-DR+ (far right, p<0.0001). I) Median distance of 
CTLs to SOX10+Ki67– (red) or SOX10+Ki67+ (blue) grouped (left, p<0.0001) (n=86). 
Matched median distance to Ki67− and Ki67+ per patient (right). J) Median distance of 
CD3+CD8+ to CD68+HLA-DR– (red) or CD68+HLA-DR+ (blue) grouped (left, p<0.0001) 
(n=97). Matched median distance to HLA-DR− and HLA-DR+ per patient (right). 
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Macrophages: Mφ. Statistical comparison performed using Mann Whitney test. *P≤0.05, 
**P≤0.01 ***P≤0.001, ****P≤0.0001. A-G images: white bars = 10μm.
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Figure 2. Infiltration of CTLs in tumor and stroma and distance of CTLs to non-proliferating 
tumor cells associates with DSS
Melanoma slides were stained for qmIF with DAPI (blue), SOX10 (red), CD3 (cyan), CD8 
(magenta), CD68 (green), Ki67 (yellow), and HLA-DR (orange). Multiplex images of 
melanoma showing A) high and B) low infiltration of CTLs in tumor. Kaplan Meier (KM) 
curves were created using classification and regression tree (CART) analysis for each 
variable shown in Figures C-H. C) High (n=57) and low (n=7) density of CD3+CD8+ cells 
in the stroma (p=0.0038). D) High (n=38) and low (n=26)CD3+CD8+ cells in the tumor 
(p=0.0147). E) High (n=57) and low (n=7) density of CD3+CD8+ HLA-DR+ cells in the 
stroma (p=0.0005). F) High (n=38) and low (n=26) density ofCD3+CD8+HLA-DR+ cells in 
the tumor (p=0.0167). G) Far (n=7) and Close (n=54) sistance of CD3+CD8+ cells to 
SOX10+Ki67− tumor cells (p=0.0006). H) Far (n=25) and Close (n=29) distance from 
CD3+CD8+ cells to proliferating (SOX10+Ki67+) tumor cells (p=0.0618).Statistical 
comparison performed using Log-rank (Mantel-Cox) test. ns: not significant (P>0.05), 
*P≤0.05, **P≤0.01 ***P≤0.001, ****P≤0.0001. White bars in A and B = 10μm.
Gartrell et al. Page 18





















Figure 3. High infiltration of CD68+macrophages in the tumor and stroma and close distance of 
CTLs to HLA-DR− macrophages associates with poor DSS
A) Multiplex image of a melanoma slide stained using qmIF for DAPI (blue), SOX10 (red), 
CD3 (cyan), CD8 (magenta), CD68 (green), Ki67 (yellow), and HLA-DR (orange). B) 
Multiplex image of melanoma showing DAPI (blue) and CD68 (green) for macrophages. 
KM curves were created using CART analysis for each variable shown in Figures C-H. C) 
High (n=7) and low(n=57) density of CD68+ macrophages in the stroma (p=0.0006). D) 
High (n=55) and low (n=9) density of CD68+macrophages in the tumor (p=0.0426). E) High 
(n=18) and low (n=46) density of CD68+HLA-DR− macrophages in the stroma (p=0.0013). 
F) High (n=10) and low (n=54) density of CD68+HLA-DR+ macrophages in stroma 
(p=0.0637). G) Far (n=47) and Close (n=14) distance of CTLs to HLA-DR− macrophages 
(p=0.0016). H) Far (n=9) and Close (n=52) distance of CTLs to HLA-DR+macrophages 
(p=0.0388). Statistical comparison performed using Log-rank (Mantel-Cox) test. ns: not 
significant (P>0.05), *P≤0.05, **P≤0.01 ***P≤0.001, ****P≤0.0001). White bars in A and 
B = 10μm.
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Figure 4. Close distance of CD68+HLA-DR− macrophages to CTLs associates with poor 
prognosis in stage II-III melanoma
A) Multiplex image of melanoma with selected region (left) shown again, including only 
HLA-DR, DAPI, and CD68 stains (right).White arrows: HLA-DR− macrophages. B) 
Receiver Operating Characteristic (ROC) Curve for distance of CTLs to HLA-DR− 
macrophages (Mφ) (n=61, AUC = 0.682, p=0.011) and KM curve using the AUC cutoff 
(p=0.0077), Far (n=42), Close (n-19).Statistical comparison performed using Log-rank 
(Mantel-Cox) test. **P≤0.01. White bars in A and inset = 10μm.
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Figure 5. Establishing CTL/macrophage ratio in stroma as a biomarker for stage II-III 
melanoma
CTL/macrophage ratio in the stroma using ROC curve and Cox Proportional Hazards 
Model. A) ROC curve for the CTL/macrophage ratio in the stroma (n=64, AUC = 0.724, 
p=0.026, cut off = 2.557). B) DSS KM curve using AUC cutoff (p=0.0033 in 64 patients, 
High (n=33), Low (n=31)). C) Overall survival (OS) KM curve using the AUC cutoff 
(n=104, p=0.0076, High (n=52), Low (n=52)). D) Univariable and multivariable Cox 
analysis of DSS (n=64) and OS (n=104) patients. Statistical comparison for DSS and OS 
performed using Log-rank (Mantel-Cox) test. Values in bold are significant at 
P≤0.05.*P≤0.05, **P≤0.01 ***P≤0.001, ****P≤0.0001.
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Table 1
Melanoma Patient Characteristics of the Overall Survival (OS) Cohort
Clinical Characteristics
Gender
 Male, no. (%) 75 (72.1)
 Female, no. (%) 29 (27.9)
Age
 Median, no. (range) 74.5 (22-96)
Location of Tumor
 Trunk, no. (%) 61 (58.7)
 Extremity, no. (%) 41 (39.4)
 Unknown, no. (%) 2 (1.9)
Stage
 II, no. (%) 91 (87.5)
 III, no. (%) 13 (12.5)
Pathological Characteristics
Depth (mm)
 Median, no. (range) 2.5 (0.6-26)
Ulceration
 Absent, no. (%) 36 (34.6)
 Present, no. (%) 65 (62.5)
 Unknown, no. (%) 3 (2.9)
TILs
 Absent, no. (%) 2 (1.9)
 Non-Brisk, no. (%) 59 (56.8)
 Brisk, no. (%) 33 (31.7)
 Unknown, no. (%) 10 (9.6)
Outcome Characteristics
Patient Follow Up (months)
 Median, no. (range) 45 (4-173)
OS (months)
 Alive (at least 2 years), no. (%) 31 (29.8)
 Dead, no. (%) 73 (70.2)
DSS (months)
 Alive or NED at Death, no. (%) 42 (40.4)
 Dead with melanoma, no. (%) 22 (21.2)
 Unknown, no. (%) 40 (38.4)
(TILs = Tumor Infiltrating Lymphocytes, OS = Overall Survival, DSS = Disease Specific Survival, NED = No Evidence of Disease)
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